<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111044</article-id><article-id pub-id-type="publisher-id">ACM-40013</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_47391108.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  早期应用艾司洛尔治疗射血分数减低心力衰竭合并2型糖尿病患者的临床研究
  Esmolol Combined with Metoprolol Succinate in the Treatment of Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>竺雨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>孝兹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>利方</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>丽艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院全科医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>302</fpage><lpage>311</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨射血分数降低的心力衰竭(HFrEF)合并2型糖尿病患者早期静脉应用β受体阻滞剂的疗效及安全性。方法：采取回顾性病例对照研究方法，应用青岛大学附属医院his病历系统选取2017年09月~2019年06月在青岛大学附属医院全科医学科住院的HFrEF合并2型糖尿病患者120例，根据患者是否应用艾司洛尔分成观察组和对照组，对照组采用降糖及抗心衰标准治疗加口服琥珀酸美托洛尔治疗；观察组采用降糖及抗心衰标准治疗加持续静脉泵入艾司洛尔，连用3天后改为口服琥珀酸美托洛尔。观察180天，比较2组患者在静息心率、6分钟步行试验(6-Minute Walk Test, 6MWT)、左心室射血分数(Left Ventricular Ejection Fraction, LVEF)、左心房内径(Left Atrium Diameter, LAD)、左心室舒张末期内径(Left Ventricular End Diastolic Diameter, LVEDD)等方面的差异。结果：1) 观察组在静息心率达标率、静息心率达标时间、6分钟步行试验、左心室射血分数等方面的疗效均明显优于对照组，差异有统计学意义(P &lt; 0.05)；左心房内径、左心室舒张末期内径两组对比结果无统计学差异(P &gt; 0.05)。2) 在第3天、第7天、第14天，观察组静息心率达标率(41.7%、91.7%、96.7%)明显高于对照组(5%、36.7%、83.3%)，且达标时间明显早于对照组，差异有统计学意义(P &lt; 0.05)。3) 出院后6个月内，观察组患者因心衰再住院率为7.02% (4/57)，明显低于对照组18.97% (11/58)，两组对比差异有统计学意义(P &lt; 0.01)。4) 观察期间，两组患者均未出现药物相关的肝肾功异常、症状性低血压、二度或三度房室传导阻滞、严重心动过缓等不良事件。结论：早期静脉应用艾司洛尔治疗射血分数减低心力衰竭合并2型糖尿病患者的静息心率达标时间明显提前，心功能及活动耐量明显改善。
    Objective: To explore the efficacy and safety of early intravenous β-blockers in patients with heart failure (HFrEF) with reduced ejection fraction and type 2 diabetes. Methods: A retrospective case-control study method was used to select 120 patients with HFrEF and type 2 diabetes who were hospitalized in the Department of General Medicine, the Affiliated Hospital of Qingdao University from September 2017 to June 2019 using the medical record system of the Affiliated Hospital of Qingdao University. Esmolol was divided into the observation group and the control group. The control group was treated with standard hypoglycemic and anti-heart failure treatment plus oral metoprolol succinate; the observation group was treated with hypoglycemic and anti-heart failure standard treatment plus continuous intravenous pumping. Esmolol, after 3 days of continuous use, changed to oral metoprolol succinate. Observed for 180 days, the differences in resting heart rate, 6-minute walk test (6MWT), left ventricular ejection fraction (LVEF), left atrial inner diameter (LAD), left ventricular end diastolic diameter (LVEDD), etc. were compared between the two groups. Results: 1) The observation group was significantly better than the control group in terms of resting heart rate compliance rate, resting heart rate compliance time, 6-minute walk test, and left ventricular ejection fraction, and the difference was statistically significant (P &lt; 0.05); the left atrium inner diameter and left ventricular end-diastolic diameter were not statistically different between the two groups (P &gt; 0.05). 2) On the 3rd, 7th, and 14th days, resting heart rate compliance rate of the observation group (41.7%, 91.7%, 96.7%) was significantly higher than that of the control group (5%, 36.7%, 83.3%), and the time to reach the standard was significantly earlier than that of the control group; the difference was statistically significant (P &lt; 0.05). 3) Within 6 months after discharge, the rehospitalization rate of patients in the observation group due to heart failure was 7.02% (4/57), which was significantly lower than 18.97% (11/58) of the control group. The difference between the two groups was statistically significant (P &lt; 0.01). 4) During the observation period, there were no adverse events such as drug-related liver and kidney dysfunction, symptomatic hypotension, second-degree or third-degree atrioventricular block, and severe bradycardia. Conclusion: Early intravenous application of esmolol in the treatment of patients with heart failure with reduced left ventricular ejection fraction and type 2 diabetes reduced the ejection fraction. The resting heart rate reached the target time significantly earlier, and the cardiac function and exercise tolerance were significantly improved. 
  
 
</p></abstract><kwd-group><kwd>艾司洛尔，射血分数降低的心力衰竭，2型糖尿病，静息心率, Esmolol</kwd><kwd> Heart Failure with Reduced Ejection Fraction</kwd><kwd> Type 2 Diabetes</kwd><kwd> Resting Heart Rate (RHR)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨射血分数降低的心力衰竭(HFrEF)合并2型糖尿病患者早期静脉应用β受体阻滞剂的疗效及安全性。方法：采取回顾性病例对照研究方法，应用青岛大学附属医院his病历系统选取2017年09月~2019年06月在青岛大学附属医院全科医学科住院的HFrEF合并2型糖尿病患者120例，根据患者是否应用艾司洛尔分成观察组和对照组，对照组采用降糖及抗心衰标准治疗加口服琥珀酸美托洛尔治疗；观察组采用降糖及抗心衰标准治疗加持续静脉泵入艾司洛尔，连用3天后改为口服琥珀酸美托洛尔。观察180天，比较2组患者在静息心率、6分钟步行试验(6-Minute Walk Test, 6MWT)、左心室射血分数(Left Ventricular Ejection Fraction, LVEF)、左心房内径(Left Atrium Diameter, LAD)、左心室舒张末期内径(Left Ventricular End Diastolic Diameter, LVEDD)等方面的差异。结果：1) 观察组在静息心率达标率、静息心率达标时间、6分钟步行试验、左心室射血分数等方面的疗效均明显优于对照组，差异有统计学意义(P &lt; 0.05)；左心房内径、左心室舒张末期内径两组对比结果无统计学差异(P &gt; 0.05)。2) 在第3天、第7天、第14天，观察组静息心率达标率(41.7%、91.7%、96.7%)明显高于对照组(5%、36.7%、83.3%)，且达标时间明显早于对照组，差异有统计学意义(P &lt; 0.05)。3) 出院后6个月内，观察组患者因心衰再住院率为7.02% (4/57)，明显低于对照组18.97% (11/58)，两组对比差异有统计学意义(P &lt; 0.01)。4) 观察期间，两组患者均未出现药物相关的肝肾功异常、症状性低血压、二度或三度房室传导阻滞、严重心动过缓等不良事件。结论：早期静脉应用艾司洛尔治疗射血分数减低心力衰竭合并2型糖尿病患者的静息心率达标时间明显提前，心功能及活动耐量明显改善。</p></sec><sec id="s2"><title>关键词</title><p>艾司洛尔，射血分数降低的心力衰竭，2型糖尿病，静息心率</p></sec><sec id="s3"><title>Esmolol Combined with Metoprolol Succinate in the Treatment of Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction</title><p>Zhuyu Xue, Yan Wang, Xiaozi Guo, Lifang Zhang, Liyan Zhang, Xuejuan Zhang<sup>*</sup></p><p>Department of General Medicine, The Affiliation Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/44-1571893x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/44-1571893x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the efficacy and safety of early intravenous β-blockers in patients with heart failure (HFrEF) with reduced ejection fraction and type 2 diabetes. Methods: A retrospective case-control study method was used to select 120 patients with HFrEF and type 2 diabetes who were hospitalized in the Department of General Medicine, the Affiliated Hospital of Qingdao University from September 2017 to June 2019 using the medical record system of the Affiliated Hospital of Qingdao University. Esmolol was divided into the observation group and the control group. The control group was treated with standard hypoglycemic and anti-heart failure treatment plus oral metoprolol succinate; the observation group was treated with hypoglycemic and anti-heart failure standard treatment plus continuous intravenous pumping. Esmolol, after 3 days of continuous use, changed to oral metoprolol succinate. Observed for 180 days, the differences in resting heart rate, 6-minute walk test (6MWT), left ventricular ejection fraction (LVEF), left atrial inner diameter (LAD), left ventricular end diastolic diameter (LVEDD), etc. were compared between the two groups. Results: 1) The observation group was significantly better than the control group in terms of resting heart rate compliance rate, resting heart rate compliance time, 6-minute walk test, and left ventricular ejection fraction, and the difference was statistically significant (P &lt; 0.05); the left atrium inner diameter and left ventricular end-diastolic diameter were not statistically different between the two groups (P &gt; 0.05). 2) On the 3rd, 7th, and 14th days, resting heart rate compliance rate of the observation group (41.7%, 91.7%, 96.7%) was significantly higher than that of the control group (5%, 36.7%, 83.3%), and the time to reach the standard was significantly earlier than that of the control group; the difference was statistically significant (P &lt; 0.05). 3) Within 6 months after discharge, the rehospitalization rate of patients in the observation group due to heart failure was 7.02% (4/57), which was significantly lower than 18.97% (11/58) of the control group. The difference between the two groups was statistically significant (P &lt; 0.01). 4) During the observation period, there were no adverse events such as drug-related liver and kidney dysfunction, symptomatic hypotension, second-degree or third-degree atrioventricular block, and severe bradycardia. Conclusion: Early intravenous application of esmolol in the treatment of patients with heart failure with reduced left ventricular ejection fraction and type 2 diabetes reduced the ejection fraction. The resting heart rate reached the target time significantly earlier, and the cardiac function and exercise tolerance were significantly improved.</p><p>Keywords:Esmolol, Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes, Resting Heart Rate (RHR)</p><disp-formula id="hanspub.40013-formula29"><graphic xlink:href="//html.hanspub.org/file/44-1571893x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1571893x8_hanspub.png" /> <img src="//html.hanspub.org/file/44-1571893x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2型糖尿病是心力衰竭的重要危险因素，两者之间存在一些共同的病理生理学机制，管理具有协同效应 [<xref ref-type="bibr" rid="hanspub.40013-ref1">1</xref>]。Framingham研究 [<xref ref-type="bibr" rid="hanspub.40013-ref2">2</xref>] 表明，心率增快会增加心血管事件风险，尤其会增加心衰和全因死亡风险，且已经明确证实β受体阻滞剂可以改善HFrEF的预后。多项临床分析显示，β受体阻滞剂可使糖尿病患者明显获益 [<xref ref-type="bibr" rid="hanspub.40013-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref4">4</xref>]。口服β受体阻滞剂在慢性收缩性心力衰竭的治疗中证据充分 [<xref ref-type="bibr" rid="hanspub.40013-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref6">6</xref>]，但目前尚缺乏静脉β受体阻滞剂在心力衰竭治疗中应用的大规模随机对照临床研究 [<xref ref-type="bibr" rid="hanspub.40013-ref7">7</xref>]。为进一步探讨静脉应用β受体阻滞剂的疗效及安全性，我们通过青岛大学附属医院his病历系统选取2017年09月~2019年06月入住我科的HFrEF合并2型糖尿病患者，患者早期静脉应用艾司洛尔治疗后，观察180天，旨在为其临床应用提供用参考依据。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 对象</title><p>采取回顾性病例对照研究方法，收集2017年09月~2019年06月在青岛大学附属医院全科医学科住院的HFrEF合并2型糖尿病患者120例，纳入标准：1) 年龄为60~80岁；2) 符合2018年中国心力衰竭诊断和治疗指南及世界卫生组织WHO公布的2型糖尿病诊断标准；3) 静息窦性心率 &gt; 70次/分；4) LVEF &lt; 40%。排除标准：1) 心源性休克、急性心力衰竭失代偿性、瓣膜性心脏病、急性心梗、变异性心绞痛、急性心包炎、风湿性心脏病等；2) 二度或三度房室传导阻滞(无心脏其起搏器)、病窦综合征、心室率 &lt; 50次/分、严重的室上性或室性心律失常；3) 血栓性静脉炎或心内血栓、伴有坏疽危险的严重外周血管疾病；4) 未控制的高血压及症状性低血压(收缩压 &lt; 90 mmHg)；5) 血肌酐 &gt; 150 mmoL/L；6) 慢性阻塞性肺疾病、肺心病或肺血管疾病、明显的支气管痉挛、支气管哮喘；7) 对β受体阻滞剂过敏；8) 近2周内服用过影响心率的药物；9) 甲状腺疾病、1型糖尿病、恶性肿瘤、精神障碍及生活不能自理。本研究经医院伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 一般资料</title><p>通过青岛大学附属医院his系统收集入选患者病历资料，包括年龄、性别、吸烟史、饮酒史、血压、体重指数(BMI)、实验室检验(糖化血红蛋白、低密度脂蛋白、脑利钠肽等)、心脏超声及用药情况等。对患者观察180天，以因心衰再入院为终点事件，共计筛选患者120例入组。根据患者是否静脉应用艾司洛尔分为观察组和对照组各60例，观察组和对照组失访率分别为5% (3/60)、3% (2/60)。</p></sec><sec id="s6_3"><title>2.3. 方法</title><p>两组患者入院当天根据症状体征应用降糖及标准抗心衰治疗，包括利尿剂、强心药、血管扩张药、正性肌力药等。对照组入院当天应用标准抗心衰治疗同时口服琥珀酸美托洛尔(生产厂家：阿斯利康制药有限公司 批准文号：H20100167) 23.75 mg，qd起始治疗；观察组入院当天采用标准抗心衰治疗外持续静脉泵入艾司洛尔(生产厂家：齐鲁制药有限公司 批准文号：H19991058)，初始剂量为0.5 mg/kg，持续进行1 min，后以0.05 mg/(kg&#183;min)持续静脉泵入，用药过程持续监测血压、心电，并根据血压、心率变化，每10~20 min调整一次剂量，每次增减0.05 mg/(kg&#183;min)，最大剂量不超过0.2 mg/(kg&#183;min)；3天后停用，继续口服琥珀酸美托洛尔23.75 mg，qd。用药过程中逐渐调整用药剂量，均以患者可耐受(心率及血压可耐受)的最大剂量为靶剂量。</p></sec><sec id="s6_4"><title>2.4. 观察指标</title><p>分别于1、2、3、7、14、28、90、180天观察患者静息心率；于1、90、180天观察6分钟步行试验距离；于90天、180天观察左心室射血分数(LVEF)、左心房内径(LAD)、左心室舒张末期内径(LVEDD)；观察6个月内因心衰再住院率。</p></sec><sec id="s6_5"><title>2.5. 测量方法</title><p>1) 静息心率测量：测量前24小时起避免进食含有酒精、咖啡因的餐饮和吸入尼古丁，测量前应禁食至少12小时，并保证睡眠充足，晨起平静休息十分钟后测量数桡动脉1分钟搏动次数，计数两次并分别记录，计算平均值。</p><p>2) 六分钟步行试验(6MWT)：按照要求在病房30米走廊进行，地面质硬、平坦、防滑、笔直，每3米进行标识，转向处显示标识。患者穿着舒适，穿适于步行的鞋子。试验前饮食应清淡，试验前无需热身，且2小时内应避免剧烈活动，患者试验过程中应使用平时步行时使用的辅助物(拐杖、助步器等)，患者在平直走廊尽可能快步行走，测定6 min的步行距离。</p><p>3) 心脏超声：应用心脏超声诊断仪和配套的矩阵超声探头，患者保持仰卧，平静呼吸，采用美国超声心电图学会推荐的方法进行扫描测量参数，包括LAD、LVEDD、双平面Simpson法计算LVEF [<xref ref-type="bibr" rid="hanspub.40013-ref8">8</xref>]。</p></sec><sec id="s6_6"><title>2.6. 统计方法</title><p>所有数据采用SPSS 22.0软件包进行统计学分析。两组之间符合正态分布的计量资料的采用( x &#175; &#177; s )表示，采用独立样本t检验进行比较；不符合正态分布的计量资料用中位数(P25，P75)表示，组间比较计采用Mann-Whitney检验；计数资料以例数表示，组间比较采用χ2检验。重复测量数据采用两因素重复测量的方差分析。生存分析采用Cox单因素回归模型，生存率的比较采用Log-rank检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者基线资料对比</title><p>两组患者在年龄、性别、吸烟史、饮酒史、血压、BMI、实验室检验、检查及用药情况等基线资料特征均无统计学差异(P &gt; 0.05)，具有可比性(见表1)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of baseline data between the two groups before treatmen</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >观察组 (n = 60例)</th><th align="center" valign="middle" >对照组 (n = 60例)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >男/女(例)</td><td align="center" valign="middle" >25/35</td><td align="center" valign="middle" >27/33</td><td align="center" valign="middle" >0.713</td></tr><tr><td align="center" valign="middle" >平均年龄(岁)</td><td align="center" valign="middle" >71.9 &#177; 4.4</td><td align="center" valign="middle" >72.4 &#177; 3.8</td><td align="center" valign="middle" >0.534</td></tr><tr><td align="center" valign="middle" >吸烟史(%)</td><td align="center" valign="middle" >26(43.3)</td><td align="center" valign="middle" >25(41.7)</td><td align="center" valign="middle" >0.853</td></tr><tr><td align="center" valign="middle" >饮酒史(%)</td><td align="center" valign="middle" >16(26.7)</td><td align="center" valign="middle" >17(28.3)</td><td align="center" valign="middle" >0.838</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >126.9 &#177; 3.7</td><td align="center" valign="middle" >127.3 &#177; 4.5</td><td align="center" valign="middle" >0.592</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >78.3 &#177; 4.0</td><td align="center" valign="middle" >77.9 &#177; 3.6</td><td align="center" valign="middle" >0.650</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >24.1 &#177; 2.7</td><td align="center" valign="middle" >23.7 &#177; 3.0</td><td align="center" valign="middle" >0.517</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mmol/L)</td><td align="center" valign="middle" >3.14 &#177; 0.6</td><td align="center" valign="middle" >3.00 &#177; 0.6</td><td align="center" valign="middle" >0.174</td></tr><tr><td align="center" valign="middle" >糖化血红蛋白(%)</td><td align="center" valign="middle" >5.65 &#177; 0.7</td><td align="center" valign="middle" >5.77 &#177; 0.8</td><td align="center" valign="middle" >0.365</td></tr><tr><td align="center" valign="middle" >静息心率(次/分)</td><td align="center" valign="middle" >90.7 &#177; 7.9</td><td align="center" valign="middle" >89.9 &#177; 6.0</td><td align="center" valign="middle" >0.549</td></tr><tr><td align="center" valign="middle" >6MWT (m)</td><td align="center" valign="middle" >321.5 &#177; 49.2</td><td align="center" valign="middle" >319.3 &#177; 45.9</td><td align="center" valign="middle" >0.807</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >BNP (ng/L)</th><th align="center" valign="middle" >1532.6 &#177; 402.3</th><th align="center" valign="middle" >1426.3 &#177; 496.5</th><th align="center" valign="middle" >0.185</th></tr></thead><tr><td align="center" valign="middle" >心功能(NYAH分级)</td><td align="center" valign="middle" >2.78 &#177; 0.4</td><td align="center" valign="middle" >2.65 &#177; 0.5</td><td align="center" valign="middle" >0.137</td></tr><tr><td align="center" valign="middle" >心脏超声</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >33.7 &#177; 2.0</td><td align="center" valign="middle" >34.1 &#177; 2.4</td><td align="center" valign="middle" >0.285</td></tr><tr><td align="center" valign="middle" >LAD (mm)</td><td align="center" valign="middle" >50.7 &#177; 2.1</td><td align="center" valign="middle" >51.0 &#177; 2.4</td><td align="center" valign="middle" >0.515</td></tr><tr><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >64.0 &#177; 1.9</td><td align="center" valign="middle" >6.36 &#177; 2.1</td><td align="center" valign="middle" >0.121</td></tr><tr><td align="center" valign="middle" >用药情况(n, %)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ACEI</td><td align="center" valign="middle" >4 (6.7)</td><td align="center" valign="middle" >6 (10)</td><td align="center" valign="middle" >0.509</td></tr><tr><td align="center" valign="middle" >ARB</td><td align="center" valign="middle" >49 (81.7)</td><td align="center" valign="middle" >46 (76.7)</td><td align="center" valign="middle" >0.500</td></tr><tr><td align="center" valign="middle" >钙离子拮抗剂</td><td align="center" valign="middle" >36 (60)</td><td align="center" valign="middle" >39 (65)</td><td align="center" valign="middle" >0.706</td></tr><tr><td align="center" valign="middle" >利尿剂</td><td align="center" valign="middle" >24 (40)</td><td align="center" valign="middle" >27 (45)</td><td align="center" valign="middle" >0.580</td></tr><tr><td align="center" valign="middle" >ARNI</td><td align="center" valign="middle" >14 (23.3)</td><td align="center" valign="middle" >11 (18.3)</td><td align="center" valign="middle" >0.654</td></tr><tr><td align="center" valign="middle" >螺内酯</td><td align="center" valign="middle" >26 (43.3)</td><td align="center" valign="middle" >30 (50)</td><td align="center" valign="middle" >0.464</td></tr><tr><td align="center" valign="middle" >二甲双胍</td><td align="center" valign="middle" >51 (85)</td><td align="center" valign="middle" >53 (88.3)</td><td align="center" valign="middle" >0.591</td></tr><tr><td align="center" valign="middle" >磺脲类药物</td><td align="center" valign="middle" >16 (26.7)</td><td align="center" valign="middle" >21 (35)</td><td align="center" valign="middle" >0.323</td></tr><tr><td align="center" valign="middle" >DPP-4抑制剂</td><td align="center" valign="middle" >37 (61.7)</td><td align="center" valign="middle" >33 (55)</td><td align="center" valign="middle" >0.459</td></tr><tr><td align="center" valign="middle" >SGLT2抑制剂</td><td align="center" valign="middle" >2 (3.3)</td><td align="center" valign="middle" >4 (6.7)</td><td align="center" valign="middle" >0.402</td></tr><tr><td align="center" valign="middle" >胰岛素</td><td align="center" valign="middle" >25 (41.7)</td><td align="center" valign="middle" >29 (48.3)</td><td align="center" valign="middle" >0.463</td></tr><tr><td align="center" valign="middle" >他汀类</td><td align="center" valign="middle" >54 (90)</td><td align="center" valign="middle" >51 (85)</td><td align="center" valign="middle" >0.394</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 治疗前两组基线资料对比</p><p>注：BMI：体质指数；1 mmHg = 0.133 kPa；6MWT：6分钟步行试验；BNP：脑利钠肽；LVEF左心室射血分数；LAD：左房内径；LVEDD：左室舒张末内径；ACEI：血管紧张素转换酶抑制剂；ARB：血管紧张素II受体拮抗剂；ARNI：沙库巴曲缬沙坦；DPP-4抑制剂：二肽基肽酶4抑制剂；SGLT2抑制剂：钠-葡萄糖协同转运蛋白2抑制剂。</p></sec><sec id="s7_2"><title>3.2. 两组患者静息心率对比</title><p>分别于第1、2、3、7、14、28、90、180天记录两组患者的静息心率(见表2)，应用重复测量的方差分析绘制心率随时间变化的趋势图。两组静息心率动态观察对比，观察组静息心率均低于对照组，第1、2、3、7天两组静息心率对比，差异有统计学意义(P &lt; 0.05)，第14、28、90、180天两组静息心率对比，差异无统计学意义(P &gt; 0.05)；不同观察时间，心率较前下降幅度也有不同，随着时间延长，两组患者静息心率下降速度逐渐减慢，以前3天下降幅度最大，第7天以后，两组患者平均静息心率水平趋于相近(见图1)。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of heart rate (times/min) at each time point during the observation period between the two group</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >观察组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >基线心率</td><td align="center" valign="middle" >90.7 &#177; 7.9</td><td align="center" valign="middle" >89.9 &#177; 6.0</td><td align="center" valign="middle" >0.549</td></tr><tr><td align="center" valign="middle" >D1</td><td align="center" valign="middle" >81.7 &#177; 7.5</td><td align="center" valign="middle" >84.3 &#177; 6.0</td><td align="center" valign="middle" >0.038</td></tr><tr><td align="center" valign="middle" >D2</td><td align="center" valign="middle" >72.3 &#177; 6.8</td><td align="center" valign="middle" >79.0 &#177; 5.5</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >D3</td><td align="center" valign="middle" >60.7 &#177; 3.4</td><td align="center" valign="middle" >71.4 &#177; 4.7</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >D7</td><td align="center" valign="middle" >59.1 &#177; 1.7</td><td align="center" valign="middle" >61.1 &#177; 1.8</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >D14</th><th align="center" valign="middle" >58.8 &#177; 1.5</th><th align="center" valign="middle" >59.3 &#177; 1.8</th><th align="center" valign="middle" >0.105</th></tr></thead><tr><td align="center" valign="middle" >D28</td><td align="center" valign="middle" >58.2 &#177; 1.6</td><td align="center" valign="middle" >58.7 &#177; 1.5</td><td align="center" valign="middle" >0.075</td></tr><tr><td align="center" valign="middle" >D90</td><td align="center" valign="middle" >57.7 &#177; 1.5</td><td align="center" valign="middle" >58.1 &#177; 1.3</td><td align="center" valign="middle" >0.121</td></tr><tr><td align="center" valign="middle" >D180</td><td align="center" valign="middle" >57.2 &#177; 1.4</td><td align="center" valign="middle" >57.6 &#177; 1.4</td><td align="center" valign="middle" >0.088</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 两组患者观察期间各时间点心率(次/分)对比</p><p>图1. 静息心率随时间变化趋势图</p></sec><sec id="s7_3"><title>3.3. 两组患者静息心率达标情况对比</title><p>观察两组患者静息心率，以55~60次/分为达标心率 [<xref ref-type="bibr" rid="hanspub.40013-ref9">9</xref>]。观察组第2天出现达标心率，对照组第3天出现达标心率，将第3天、第7天、第14天两组患者静息心率达标率对比，观察组静息心率达标率(41.7%、91.7%、96.7%)明显高于对照组(5%、36.7%、83.3%)，且达标时间明显早于对照组，差异有统计学意义(P &lt; 0.05) (见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of resting heart rate normalization between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >第3天</th><th align="center" valign="middle"  colspan="2"  >第7天</th><th align="center" valign="middle"  colspan="2"  >第14天</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >达标(n, %)</td><td align="center" valign="middle" >未达标(n, %)</td><td align="center" valign="middle" >达标(n, %)</td><td align="center" valign="middle" >未达标(n, %)</td><td align="center" valign="middle" >达标(n, %)</td><td align="center" valign="middle" >未达标(n, %)</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >25 (41.7)</td><td align="center" valign="middle" >35 (58.3)</td><td align="center" valign="middle" >55 (91.7)</td><td align="center" valign="middle" >5 (8.3)</td><td align="center" valign="middle" >58 (96.7)</td><td align="center" valign="middle" >2 (3.3)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >3 (5)</td><td align="center" valign="middle" >57 (95)</td><td align="center" valign="middle" >22 (36.7)</td><td align="center" valign="middle" >38 (63.3)</td><td align="center" valign="middle" >50 (83.3)</td><td align="center" valign="middle" >10 (16.7)</td></tr><tr><td align="center" valign="middle" >χ2</td><td align="center" valign="middle"  colspan="2"  >20.54</td><td align="center" valign="middle"  colspan="2"  >39.47</td><td align="center" valign="middle"  colspan="2"  >27.22</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >&lt;0.01</td><td align="center" valign="middle"  colspan="2"  >&lt;0.01</td><td align="center" valign="middle"  colspan="2"  >&lt;0.01</td></tr></tbody></table></table-wrap><p>表3. 两组患者静息心率达标情况对比</p></sec><sec id="s7_4"><title>3.4. 两组患者心功能指标对比</title><p>观察两组患者心功能指标，6MWT、LVEF较前均有增加，LAD、LVEDD、BNP较前均有减小，结果有统计学差异(P &lt; 0.05) (见表4)。对比两组患者第180天心功能指标，两组患者6MWT、LVEF对比结果有统计学差异(P &lt; 0.05)，LAD、LVEDD、BNP对比差异无统计学意义(P &gt; 0.05) (见表5)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of inner function indexes between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="5"  >观察组</th><th align="center" valign="middle"  colspan="5"  >对照组</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >6MWT (m)</td><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >LAD (mm)</td><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >BNP (ng/L)</td><td align="center" valign="middle" >6MWT (m)</td><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >LAD (mm)</td><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >BNP (ng/L)</td></tr><tr><td align="center" valign="middle" >第1天</td><td align="center" valign="middle" >321.5 &#177; 49.2</td><td align="center" valign="middle" >33.7 &#177; 2.02</td><td align="center" valign="middle" >50.7 &#177; 2.11</td><td align="center" valign="middle" >64.0 &#177; 1.86</td><td align="center" valign="middle" >1532.6 &#177; 402.3</td><td align="center" valign="middle" >319.3 &#177; 45.9</td><td align="center" valign="middle" >34.1 &#177; 2.38</td><td align="center" valign="middle" >51.0 &#177; 2.40</td><td align="center" valign="middle" >63.6 &#177; 2.05</td><td align="center" valign="middle" >1426.3 &#177; 496.5</td></tr><tr><td align="center" valign="middle" >第90天</td><td align="center" valign="middle" >353.4 &#177; 40.1<sup>#</sup></td><td align="center" valign="middle" >36.4 &#177; 1.94<sup>#</sup></td><td align="center" valign="middle" >48.1 &#177; 1.92<sup>#</sup></td><td align="center" valign="middle" >60.1 &#177; 2.41<sup>#</sup></td><td align="center" valign="middle" >1134.4 &#177; 359.6<sup>#</sup></td><td align="center" valign="middle" >335.6 &#177; 31.7<sup>#</sup></td><td align="center" valign="middle" >26.1 &#177; 2.01<sup>#</sup></td><td align="center" valign="middle" >49.6 &#177; 2.01<sup>#</sup></td><td align="center" valign="middle" >61.5 &#177; 2.52<sup>#</sup></td><td align="center" valign="middle" >1257.9 &#177; 375.4<sup>#</sup></td></tr><tr><td align="center" valign="middle" >第180天</td><td align="center" valign="middle" >404.2 &#177; 32.7 *</td><td align="center" valign="middle" >40.1 &#177; 1.7*</td><td align="center" valign="middle" >47.9 &#177; 1.9*</td><td align="center" valign="middle" >58.6 &#177; 3.1*</td><td align="center" valign="middle" >916.3 &#177; 313.1*</td><td align="center" valign="middle" >393.5 &#177; 26.4*</td><td align="center" valign="middle" >39.5 &#177; 1.9*</td><td align="center" valign="middle" >48.8 &#177; 1.7*</td><td align="center" valign="middle" >59.4 &#177; 2.6*</td><td align="center" valign="middle" >1046.7 &#177; 301.3*</td></tr></tbody></table></table-wrap><p>表4. 两组患者组内心功能指标对比</p><p>注1：6MWT：6分钟步行试验；BNP：脑利钠肽；LVEF左心室射血分数；LAD：左房内径；LVEDD：左室舒张末内径。注2：组内第1天vs第90天，#P &lt; 0.05；组内第1天vs第180天，*P &lt; 0.05。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of cardiac function indexes between the two groups on the 180th da</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >观察组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >6MWT (m)</td><td align="center" valign="middle" >404.2 &#177; 32.7</td><td align="center" valign="middle" >393.5 &#177; 26.4</td><td align="center" valign="middle" >0.038</td></tr><tr><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >40.1 &#177; 1.7</td><td align="center" valign="middle" >39.5 &#177; 1.9</td><td align="center" valign="middle" >0.045</td></tr><tr><td align="center" valign="middle" >LAD (mm)</td><td align="center" valign="middle" >47.9 &#177; 1.9</td><td align="center" valign="middle" >48.8 &#177; 1.7</td><td align="center" valign="middle" >0.086</td></tr><tr><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >58.6 &#177; 3.1</td><td align="center" valign="middle" >59.4 &#177; 2.6</td><td align="center" valign="middle" >0.095</td></tr><tr><td align="center" valign="middle" >BNP (ng/L)</td><td align="center" valign="middle" >916.3 &#177; 313.1</td><td align="center" valign="middle" >1046.7 &#177; 301.3</td><td align="center" valign="middle" >0.056</td></tr></tbody></table></table-wrap><p>表5. 两组患者第180天组间心功能指标对比</p><p>注：6MWT：6分钟步行试验；BNP：脑利钠肽；LVEF左心室射血分数LAD：左房内径；LVEDD：左室舒张末内径。</p></sec><sec id="s7_5"><title>3.5. 两组患者出院后6个月内因心衰再入院情况比较</title><p>出院后6个月内，观察组患者因心衰再住院率为7.02% (4/57)，明显低于对照组18.97% (11/58)，将两组患者因心衰再住院定义为终点事件绘制生存曲线，两组对比，差异有统计学意义(P &lt; 0.01) (见图2)。</p><p>图2. 生存曲线</p></sec><sec id="s7_6"><title>3.6. 不良反应</title><p>观察过程中，两组患者均未出现药物相关的肝肾功异常、症状性低血压、二度或三度房室传导阻滞、严重心动过缓等不良事件。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>2型糖尿病患者因代谢紊乱、微循环障碍等改变了机体交感神经和副交感神经活性，从而引起心脏自主神经病变，影响心率和血管张力的调节 [<xref ref-type="bibr" rid="hanspub.40013-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref11">11</xref>]。HFrEF合并2型糖尿病患者静息心率增快与交感神经活动增强、胰岛素抵抗和代谢障碍有关 [<xref ref-type="bibr" rid="hanspub.40013-ref12">12</xref>]。多项研究显示，心率增快与心衰严重程度及预后密切相关，是心血管疾病的独立危险因子 [<xref ref-type="bibr" rid="hanspub.40013-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref17">17</xref>]。</p><p>心衰指南 [<xref ref-type="bibr" rid="hanspub.40013-ref8">8</xref>] 推荐HFrEF患者应用β受体阻滞剂控制静息心率，但对β受体阻滞剂药物剂型未给出明确建议。静脉应用β受体阻滞剂可以迅速提升血药浓度，有效抑制交感活性；持续静脉泵入，可实现匀速给药、剂量可控，从而达到稳定的血药浓度。有研究表明，慢性心力衰竭患者的治疗目标更应致力于早期控制心率 [<xref ref-type="bibr" rid="hanspub.40013-ref18">18</xref>]。本研究中将两组患者不同观察时间得到的静息心率进行对比，绘制折线图，结果显示观察组心率下降水平及速度较对照组明显；此结果表明，早期静脉应用β受体阻滞剂，对于HFrEF合并2型糖尿病患者控制静息心率效果优于单药口服。心衰指南指出HFrEF患者总体目标心率为55~60次/分 [<xref ref-type="bibr" rid="hanspub.40013-ref9">9</xref>]，观察组、对照组在第7天及第14天平均心率分别为59.1次/分、58.8次/分和61.1次/分、59.3次/分，观察组总体平均心率达标时间明显早于对照组，差异有统计学意义(P &lt; 0.05)。观察组、对照组分别于第2天和第3天出现达标心率，因此将第3、7、14天两组患者静息心率达标率对比，观察组静息心率达标率(41.7%、91.7%、96.7%)明显高于对照组(5%、36.7%、83.3%)，且达标时间明显早于对照组，差异有统计学意义(P &lt; 0.05)。此结果表明早期静脉应用β受体阻滞剂可使HFrEF合并2型糖尿病患者心率达标时间明显提前，达标率明显提高。</p><p>MERIT-HF、CIBISII、US Carvedilol HF Study等 [<xref ref-type="bibr" rid="hanspub.40013-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.40013-ref21">21</xref>] 研究已证实，与安慰剂相比，应用β受体阻滞剂可使HFrEF患者心血管死亡或住院风险降低27%~38%，并提高患者生活质量。本研究结果显示，两组患者6分钟步行试验、LVEF、LAD、LVEDD、BNP较前均有改善，结果有统计学差异(P &lt; 0.05)。在第180天，对比两组患者心功能指标，其中两组患者6MWT、LVEF对比结果有统计学差异(P &lt; 0.05)，LAD、LVEDD、BNP对比差异无统计学意义(P &gt; 0.05)。此结果表明早期静脉应用β受体阻滞剂对于HFrEF合并2型糖尿病患者可有效改善其活动量及生存质量。对于LAD、LVEDD等反映心脏舒张功能的指标，两组患者结果对比无明显差异，考虑可能与静脉应用β受体阻滞剂时间较短有关。</p><p>Pocock等研究发现，慢性心衰患者应用β受体阻滞剂可使其再住院率降低28%~36% [<xref ref-type="bibr" rid="hanspub.40013-ref6">6</xref>]，这与β受体阻滞剂减慢心率、抗心律失常、预防心肌细胞凋亡、上调β受体功能等多方面有关。Oliver等学者研究发现有34项荟萃分析(66个随机对照试验，35,383名患者)显示HFrEF患者应用β受体阻滞剂可降低死亡率和住院率 [<xref ref-type="bibr" rid="hanspub.40013-ref22">22</xref>]。本研究以两组患者因心衰再入院为终点事件绘制生存曲线，结果显示观察组因心衰再入院率(7.02%)低于对照组(18.97%)，差异有统计学意义(P &lt; 0.01)。患者再入院后行动态心电图检查，结果显示，观察期间，对照组患者发生恶性心律失常事件次数(6次)明显多于观察组(2次)，且出现的平均时间(58.3天)早于观察组(117.5天)；此结果表明对于HFrEF合并2型糖尿病患者早期静脉应用β受体阻滞剂降低心率能有效控制恶性心律失常事件的发生及发生时间。本研究观察过程中，两组患者治疗后血压有所下降，但均可耐受，未出现症状性低血压，整个治疗过程中均未发生药物相关的严重不良反应，提示静脉应用β受体阻滞剂安全性较好。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，HFrEF合并2型糖尿病患者早期静脉应用艾司洛尔控制心率，可使患者静息心率达标时间明显提前，达标率明显提高，活动及生活质量提高，且安全性与单药口服无明显差异，具有临床应用价值。此外，因本研究样本量小、为单中心研究，可能存在偏倚，因此需要更大规模研究进行探究。</p></sec><sec id="s10"><title>利益冲突</title><p>所有作者声明不存在利益冲突。</p></sec><sec id="s11"><title>基金项目</title><p>心血管多学科整合思维研究基金(CIMF-Z-2016-23-1823)。</p></sec><sec id="s12"><title>文章引用</title><p>薛竺雨,王 燕,郭孝兹,张利方,张丽艳,张雪娟. 早期应用艾司洛尔治疗射血分数减低心力衰竭合并2型糖尿病患者的临床研究Esmolol Combined with Metoprolol Succinate in the Treatment of Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction[J]. 临床医学进展, 2021, 11(01): 302-311. https://doi.org/10.12677/ACM.2021.111044</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40013-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dunlay, S.M., Givertz, M.M., Aguilar, D., et al. (2019) Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement from the American Heart Association and the Heart Failure Society of America. Circulation, 140, e294-e324. 
&lt;br&gt;https://doi.org/10.1016/j.cardfail.2019.05.007</mixed-citation></ref><ref id="hanspub.40013-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ho, J.E., Larson, M.G., Ghorbani, A., et al. (2014) Long-Term Cardiovascular Risks Associated with an Elevated Heart Rate: The Framingham Heart Study. Journal of the American Heart Association, 3, e000668.  
&lt;br&gt;https://doi.org/10.1161/JAHA.113.000668</mixed-citation></ref><ref id="hanspub.40013-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C.C., Hess, C.N., Hiatt, W.R., et al. (2016) Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus—Mechanisms, Management, and Clinical Considerations. Circulation, 133, 2459-2502. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.116.022194</mixed-citation></ref><ref id="hanspub.40013-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中国医师协会心力衰竭专业委员会. 静脉β肾上腺素能受体阻滞剂临床规范化应用中国专家建议[J]. 中华心力衰竭和心肌病杂志, 2017(1): 7-14.</mixed-citation></ref><ref id="hanspub.40013-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Zhang, J., Butler, J., et al. (2017) Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results from the China Heart Failure (China-HF) Registry. Journal of Cardiac Failure, 23, 868-875. &lt;br&gt;https://doi.org/10.1016/j.cardfail.2017.09.014</mixed-citation></ref><ref id="hanspub.40013-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Pocock, S.J., Ariti, C.A., McMurray, J.J., et al. (2013) Predicting Survival in Heart Failure: A Risk Score Based on 39 372 Patients from 30 Studies. European Heart Journal, 34, 1404-1413. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehs337</mixed-citation></ref><ref id="hanspub.40013-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Shavadia, J., Zheng, Y., Green, J.B., et al. (2019) Associations between Beta-Blocker Therapy and Cardiovascular Outcomes an Patients with Diabetes and Established Atherosclerotic Cardiovascular Disease: Insights from the Tecos Study. Journal of the American College of Cardiology, 73, 138. &lt;br&gt;https://doi.org/10.1016/S0735-1097(19)30746-6</mixed-citation></ref><ref id="hanspub.40013-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">崔波, 郑昭芬, 危安. 双平面Simpson法在急性心力衰竭的临床应用[J]. 中国医学工程, 2018, 26(10): 15-17.</mixed-citation></ref><ref id="hanspub.40013-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018(4): 196-225.</mixed-citation></ref><ref id="hanspub.40013-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Shah, A.S., Jaiswal, M., Dabelea, D., et al. (2020) Cardiovascular Risk and Heart Rate Variability in Young Adults with Type 2 Diabetes and Arterial Stiffness: The Search for Diabetes in Youth Study. Journal of Diabetic Complications, 34, Article ID: 107676. &lt;br&gt;https://doi.org/10.1016/j.jdiacomp.2020.107676</mixed-citation></ref><ref id="hanspub.40013-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Spallone, V., Ziegler, D., Freeman, R., et al. (2011) Cardiovascular Autonomic Neuropathy in Diabetes: Clinical Impact, Assessment, Diagnosis, and Management. Diabetes/Metabolism Research and Reviews, 27, 639-653.  
&lt;br&gt;https://doi.org/10.1002/dmrr.1239</mixed-citation></ref><ref id="hanspub.40013-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Munroe, P.B., Ramirez, J. and van Duijvenboden, S. (2019) Resting Heart Rate and Type 2 Diabetes: A Complex Relationship in Need of Greater Understanding. Journal of the American College of Cardiology, 74, 2175-2177.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2019.08.1030</mixed-citation></ref><ref id="hanspub.40013-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sanchez-Marteles, M., Rubio Gracia, J. and Gimenez Lopez, I. (2016) Pathophysiology of Acute Heart Failure: A World to Know. Revista Clínica Española, 216, 38-46. &lt;br&gt;https://doi.org/10.1016/j.rceng.2015.09.007</mixed-citation></ref><ref id="hanspub.40013-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Prado, A., Dufek, J., Navalta, J., et al. (2017) A First Look into the Influence of Triathlon Wetsuit on Resting Blood Pressure and Heart Rate Variability. Biology of Sport, 34, 77-82. &lt;br&gt;https://doi.org/10.5114/biolsport.2017.63737</mixed-citation></ref><ref id="hanspub.40013-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kotecha, D., Flather, M.D., Altman, D.G., et al. (2017) Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients with Heart Failure. Journal of the American College of Cardiology, 69, 2885-2896.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2017.04.001</mixed-citation></ref><ref id="hanspub.40013-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Varian, K.D., Ji, X., Grodin, J.L., et al. (2020) Resting Heart Rate in Ambulatory Heart Failure with Reduced Ejection Fraction Treated with Beta-Blockers. ESC Heart Fail, 7, 3049-3058. &lt;br&gt;https://doi.org/10.1002/ehf2.12931</mixed-citation></ref><ref id="hanspub.40013-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zareini, B., Blanche, P., D’Souza, M., et al. (2020) Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. Circulation: Cardiovascular Quality and Outcomes, 13, e006260. &lt;br&gt;https://doi.org/10.1161/CIRCOUTCOMES.119.006260</mixed-citation></ref><ref id="hanspub.40013-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">张文颖, 郑燕琳, 周金敬. 伊伐布雷定联合小剂量β-受体阻滞剂治疗慢性心力衰竭的临床疗效[J]. 临床合理用药杂志, 2020, 13(15): 1-3.</mixed-citation></ref><ref id="hanspub.40013-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Savva, J., Maqbool, A.W., Hazel, L., et al. (2009) Polymorphisms of Adrenoceptors Are Not Associated with an Increased Risk of Adverse Event in Heart Failure: A MERIT-HF Sub-Study. Journal of Cardiac Failure, 15, 435-441.  
&lt;br&gt;https://doi.org/10.1016/j.cardfail.2008.12.005</mixed-citation></ref><ref id="hanspub.40013-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Levy, P., Lechat, Ph., Leizorovicz, A. and Levy, E. (1998) A Cost-Minimization of Heart Failure Therapy with Bisoprolol in the French Setting: An Analysis from CIBIS Trial Data. Cardiovascular Drugs and Therapy, 12, 301-305.  
&lt;br&gt;https://doi.org/10.1023/A:1007773901631</mixed-citation></ref><ref id="hanspub.40013-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南(第2版) [J]. 中国医学前沿杂志(电子版), 2019, 11(7): 1-78.</mixed-citation></ref><ref id="hanspub.40013-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Oliver, J., Monica, S., James, P., et al. (2020) Beta-Blocker Efficacy across Different Cardiovascular Indications: An Umbrella Review and Meta-Analytic Assessment. BMC Medicine, 18, 103.  
&lt;br&gt;https://doi.org/10.1186/s12916-020-01564-3</mixed-citation></ref></ref-list></back></article>